MedTrace Logo

PF-06372865 In Subjects With Chronic Low Back Pain

NCT02262754 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 302

Last updated 2017-01-04

Study results available
· View outcomes & findings →

Summary

PF-06372865 In Subjects With Chronic Low Back Pain

Conditions

  • Chronic Low Back Pain

Interventions

DRUG

PF-06372865

Dose level 1 daily dosing BID for 1 week followed by dose level 2 daily BID for 3 weeks

DRUG

Placebo

Placebo for PF-06372865 and placebo for naproxen daily

DRUG

Naproxen

500 mg BID for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02262754 on ClinicalTrials.gov